2023 Leads Patients Pharmaceutical manufacturing 
European Pharmaceutical Review
JANUARY 9, 2024
Revolutionising quality control In the backdrop of stringent quality standards and regulatory demands inherent to pharmaceutical manufacturing, the addition of AI technologies introduce a paradigm shift. Figure 1 : adapted from Saha, G. Tuijin Jishu/Journal of Propulsion Technology, 44(3), 1384-1392.
Prognos Health
MAY 31, 2023
Todd Somsel , Commercial Lead, RWD Marketplace The acceptance and application of real-world evidence (RWE) by stakeholders across the healthcare industry continues its rapid pace of growth. One of the key pillars of understanding is in the quality of the evidence, and its underlying real-world data (RWD).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Prognos Health
MAY 31, 2023
Todd Somsel , Commercial Lead, RWD Marketplace The acceptance and application of real-world evidence (RWE) by stakeholders across the healthcare industry continues its rapid pace of growth. One of the key pillars of understanding is in the quality of the evidence, and its underlying real-world data (RWD).
European Pharmaceutical Review
MAY 31, 2023
The inventory position of 28 major pharmaceutical manufacturers in 2022 has been revealed in an annual report. It investigated how excessive inventories are affecting the industry and what factors could influence inventory growth in 2023. This makes it difficult to respond swiftly to changes in demand, the report found.
European Pharmaceutical Review
OCTOBER 12, 2023
September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. Research by the Confederation of British Industry (CBI) , released in September this year, highlighted progress for UK manufacturing in its latest Industrial Trends Survey. Meath opened last month.
PM360
OCTOBER 25, 2023
Combination Therapy in Oncology Combination therapies comprising two or more therapeutic agents have become a cornerstone of oncology management and are increasingly a development focus for the pharmaceutical industry. When 1+1 ≠2 In theory, combining two or more branded agents can lead to a price that exceeds SoC monotherapy.
Clarify Health
OCTOBER 26, 2021
By enrolling participants with a wide range of baseline characteristics, study populations will more accurately reflect the patients likely to take the drug if it is approved. Cancer patients treated in clinical trials live substantially longer than those not treated in trials and benefit from lower hospital readmissions. 2] Figure 1.
Expert insights. Personalized for you.
122 
Let's personalize your content